Trials / Completed
CompletedNCT01741194
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 418 (actual)
- Sponsor
- Cerecin · Industry
- Sex
- All
- Age
- 66 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AC-1204 | AC-1204 taken once daily, by mouth |
| DRUG | Placebo | Placebo taken once daily, by mouth |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2016-10-24
- Completion
- 2017-04-14
- First posted
- 2012-12-04
- Last updated
- 2021-08-02
Locations
82 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01741194. Inclusion in this directory is not an endorsement.